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Abstract
The production of cells capable of expressing gene(s) of interest is important for a variety of applications in biomedicine and
biotechnology, including gene therapy and animal transgenesis. The ability to insert transgenes at a precise location in the
genome, using site-specific recombinases such as Cre, FLP, and WC31, has major benefits for the efficiency of transgenesis.
Recent work on integrases from WC31, R4, TP901-1 and Bxb1 phages demonstrated that these recombinases catalyze site-
specific recombination in mammalian cells. In the present study, we examined the activities of integrases on site-specific
recombination and gene expression in mammalian cells. We designed a human artificial chromosome (HAC) vector
containing five recombination sites (WC31 attP,R 4attP, TP901-1 attP, Bxb1 attP and FRT; multi-integrase HAC vector) and de
novo mammalian codon-optimized integrases. The multi-integrase HAC vector has several functions, including gene
integration in a precise locus and avoiding genomic position effects; therefore, it was used as a platform to investigate
integrase activities. Integrases carried out site-specific recombination at frequencies ranging from 39.3–96.8%. Additionally,
we observed homogenous gene expression in 77.3–87.5% of colonies obtained using the multi-integrase HAC vector. This
vector is also transferable to another cell line, and is capable of accepting genes of interest in this environment. These data
suggest that integrases have high DNA recombination efficiencies in mammalian cells. The multi-integrase HAC vector
enables us to produce transgene-expressing cells efficiently and create platform cell lines for gene expression.
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Introduction
Many methods are available to produce transgenic cells for the
functional studies of genes, drug discovery and gene therapy. The
most common method used to produce these cells relies on
random integration of the gene after transfection of plasmid DNA
or transduction with viruses. These methods are followed by
antibiotic selection of a stable pool of cells and functional screening
to identify individual clones that have the correct function(s).
However, random integration into chromosomes is inefficient [1],
and the expression levels of genes vary greatly due to positional
effects and the number of copies inserted [2,3,4,5]. As a result, the
process of generating and selecting gene expression cells can be
labor intensive and extremely time consuming. It is a widely held
view that new gene expression technology for mammalian cells
should optimally include targeting the gene to a transcriptional
‘hot spot’ in the genome [6]. Although homologous recombination
for targeted integration is very specific, it suffers from exceedingly
low frequencies [7].
To increase the speed and efficiency of generating transgenic
cells, alternative technologies have been considered. The site-
specific gene recombination systems, such as bacteriophage P1-
derived Cre, yeast-derived FLP, and phage integrases typified by
bacteriophage WC31-derived integrase, are example of these.
These systems have been used widely for the targeted recombi-
nation of transgenes into the genome of mammalian cells [8].
Additionally, these site-specific recombinases can induce the
deletion or inversion of DNA sequences leading to conditional
gene inactivation or expression [9]. The most powerful tool for
site-specific recombination in vitro [10,11] and in vivo [12,13] is Cre
recombinase, which catalyzes reciprocal site-specific recombina-
tion between two loxP sites. A second site-specific recombinase,
FLPe, based on FLP from Saccharomyces cerevisiae, has also been used
in mammalian cells and recognizes distinct FRT sites [14]. FLPe is
an improved and temperature stable version of the FLP
recombinase. However, in assays with chromosomally located
FRT sites, the efficiency of FLPe only exhibits 10% Cre
recombination activity [15]. A third class of site-specific recombi-
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displays activity in mammalian cells. Tyrosine integrases such as l
phage integrase are also used in mammalian cells [16,17].
However, the recombination efficiency of tyrosine family inte-
grases is lower than that of serine family integrases, and we
therefore used serine integrases in this study [18].
The WC31 integrase was originally isolated from a Streptomyces
phage [19], and the 605 amino acid WC31 integrase can perform
recombination between attP and attB sites, which is different to Cre
and FLPe in human cells [20]. Recombination between attP and
attB sites generates hybrid attL or attR sites that are no longer
substrates for the integrase in the absence of additional cofactors
[20,21]. Furthermore, WC31 integrase facilitates integration of
attB-bearing plasmids at endogenous sequences with partial
identity to attP. These are termed pseudo attP sites [22]. The
ability of WC31 integrase to mediate transgene integration into
native pseudo attP sites has been used in gene therapy experiments
to produce therapeutically useful levels of Factor IX, correct
human type VII collagen genes in human keratinocytes that
contained mutants of this gene [18], and to produce dystrophin in
mouse muscle-derived stem cells, human myoblasts and mouse
muscle [23,24]. In addition, WC31 integrase has been used in the
construction and manipulation of transgenic animals [25,26,27].
Based on these favorable results with WC31 integrase, other serine
integrases from phages such as R4, TP901-1 and Bxb1, have been
evaluated in mammalian cells. The R4 integrase (469 amino acids)
is a site-specific, unidirectional recombinase derived from the
genome of phage R4 of Streptomyces parvulus [28,29]. The TP901-1
integrase (485 amino acids) is encoded by phage TP901-1 of
Lactococcus lactis subsp [30,31]. The Bxb1 integrase (500 amino
acids) is derived from mycobacteriophage Bxb1, which is a
temperate phage of Mycobacterium smegmatis [32,33]. Recent work
on integrases from R4, TP901-1 and Bxb1 phages demonstrates
that these enzymes mediate DNA recombination at heterotypic
binding sequences known as attB and attP sites in mammalian cells
[28,30,34]. One report suggests that WC31 integrase may have
high recombination efficiency (87%), similar to Cre, in mediating
recombination in cultured cells [15]. However, other integrases
have demonstrated more limited success, and thus the broad utility
of phage integrases as a tool remains to be established. Codon
usage bias has been reported for many organisms, from viruses to
eukaryotes [35]. If a gene contains codons that are rarely used in
the host, its level of expression will not be maximal. Codon-
optimization involves altering the rare codons in the target gene so
that they more closely reflect the codon usage of the host, without
modifying the amino acid sequence of the encoded protein. The
ability of phage integrases, from phages WC31, R4, TP901-1 and
Bxb1, to carry out efficient and precise recombination between
their attP and attB sequences in mammalian cells will make them
new and valuable genetic tools for the engineering of complex
genomes.
Human artificial chromosomes (HACs) are highly promising
gene delivery tools that possess several advantages over conven-
tional gene delivery systems [36,37]. We recently produced HAC
vectors by deleting all of the endogenous genes on human
chromosome 21 [38,39]. Like native chromosomes, the HAC
vector has the capacity to replicate and segregate autonomously
without integration into the host genome. The genomic context of
the host chromosome is disrupted by the transgene [40] and
expression of the transgene is ruled by positional effects, due to
random integration. The HAC vector can avoid effects on both
the transgene and the host genome. Therefore, we considered that
the HAC vector was an appropriate platform for measuring site-
specific recombination activities of phage integrases in various
mammalian cells. Additionally, the HAC vector was transferred
from Chinese hamster ovary (CHO) cells to various other mouse
and human cell lines by microcell-mediated chromosome transfer
(MMCT) [38,41,42]. The CHO cell line, which is a capable
microcell donor, has been used as an intermediate host of
transferable chromosome fragments to other cell lines [43].
In this study, we designed a HAC-based multi-integrase system
containing five recombination sites (WC31 attP,R 4attP, TP901-1
attP, Bxb1 attP and FRT) and integrases. We carried out the
present study to examine the site-specific recombination activity
and the actual efficacy of producing transgenic mammalian cells
by these integrases.
Results
Construction of the multi-integrase HAC vector (MI-HAC
vector) in Chinese hamster ovary (CHO) cells
The multi-integrase platform had four attP phage integrase
recombination sites and an FRT site. The platform plasmid was
constructed in E. coli using the Multiple Gateway system, which is
useful in high-throughput construction of plasmids carrying
multiple DNA sequences [44,45]. The polymerase chain reaction
(PCR) fragments for FRT-PGK-WC31 attP, PGK-R4 attP, PGK-
TP901-1 attP and PGK-Bxb1 attP contained the appropriate
gateway attB sites. The four fragments were recombined into four
different donor vectors (pDONR
TM221 P1-P5r, pDONR221 P5-
P4, pDONR221 P4r-P3r, pDONR221 P3-P2) to create four entry
clones (pENTR L1-FRT-PGK-WC31-R5, pENTR L5-PGK-R4-
L4, pENTR R4-PGK-TP901-1-R3, pENTR L3-PGK-Bxb1-L2)
(Fig. 1A). DNA sequencing showed that 95.0% of kanamycin-
resistant E. coli transformant colonies were correctly targeted. The
four pENTR vectors and a pDEST vector were mixed in the
presence of LR clonase enzyme to generate the multi-integrase
platform plasmid (Fig. 1B). Using DNA sequencing, 40.7% of
ampicillin-resistant E. coli transformant colonies were correctly
targeted. The multi-integrase platform plasmid carried a loxP
sequence and the 39 hypoxanthine phosphoribosyl transferase
(HPRT) sequence. The HAC vector used in this study was
21HAC1 containing the 59 HPRT-loxP site [39]. The HPRT gene
expressed in the HAC vector conferred HAT-resistance after site-
specific recombination with the Cre/loxP system. The platform
plasmid and Cre expression vector were co-transfected into CHO
(hprt
2/2) cells carrying the HAC vector (Fig. 1C). PCR analyses
using the primers (Trans L1/R1, loxP4548/hyg696 and WC31
F1/Bxb1 R3) showed that 50.0% HAT-resistant transfectants
were correctly targeted. This ratio of circular plasmid insertion
into the 59 HPRT-loxP site on the HAC vector by HPRT gene
reconstitution was similar to that observed previously (33.3%) [39].
This HAC vector was designated as the multi-integrase HAC (MI-
HAC) vector. Using fluorescence in situ hybridization (FISH), the
digoxigenin-labeled human COT1 DNA probe localized to the
MI-HAC vector and the HAC vector was present as an
independent minichromosome without integration into the host
genome in all six randomly selected clones (data not shown). These
results indicated that a multi-integrase platform can be cloned into
the defined locus on the HAC vector by the Cre/loxP system.
Site-specific recombination into the phage attP and FRT
sites on the MI-HAC vector
In attempts to improve translational efficiency in mammalian
cells, integrases derived from phages WC31, R4, TP901-1 and
Bxb1 were codon-optimized. To compare the recombination
efficiency of the four integrases and FLPe in an identical
expression system in mammalian cells, we used the multi-integrase
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integrases and FLPe, all expression constructs were driven by the
phosphoglycerate kinase 1 (PGK) promoter (Fig. 2A).
We tested whether integrases could mediate integration at
phage attP sites more efficiently than FLPe. We also attempted to
determine which integrase had the highest recombination
efficiency. Recombinant assay plasmids carrying a promoterless
neomycin-resistance gene with a recombination site (pNeo-WC31
attB, pNeo-R4 attB, pNeo-TP901-1 attB, pNeo-Bxb1 attB or
pNeo-FRT) and the corresponding recombinase expression
plasmids (pCMV-WC31, pCMV-R4, pCMV-TP901-1, pCMV-
Bxb1, or pCMV-FLPe) were co-transfected into CHO cells
carrying the MI-HAC vector (platform
+/recombinase
+, n=5–9)
(Fig. 2A). To ensure that the recombination event that occurred at
the recombination sites on the MI-HAC vector was dependent on
recombinase expression, two control experiments were performed.
Figure 2. A direct comparison of the recombination efficiency mediated by phage integrases and FLPe. (A) Schematic diagram of the
multi-integrase HAC system facilitating direct comparison of FLPe and phage integrase recombination activities. (B) In vitro integration efficiency after
integrases and FLPe-mediated integration. A summary of the counted colonies for each condition after crystal violet staining is shown. Data were
corrected for average colony numbers in one of the ten dishes and expressed as means 6 SE. Student’s t-test was used to determine statistically
significant differences. Differences at P,0.05 were considered significant. *P,0.05, **P,0.01. (C) Site-specific recombination efficiency was
determined by genomic PCR. (D) Fluorescence in situ hybridization (FISH) analysis of the recombinant multi-integrase HAC vector in CHO cells.
Arrowheads indicate the dual-colored multi-integrase HAC vector during metaphase. Cells were probed with human COT-1 DNA (red) and each
recombinant assay plasmid conferred fluorescence to the target cell (green).
doi:10.1371/journal.pone.0017267.g002
Figure 1. Strategy for construction of the multi-integrase HAC vector. (A) Construction of entry clones (pENTR) from gateway attB-flanked
PCR products and donor vectors (pDONR). (B) Construction of the multi-integrase platform plasmid from four entry clones and a destination vector
(pDEST). (C) Construction of the HAC vector containing the multi-integrase platform using Cre/loxP system.
doi:10.1371/journal.pone.0017267.g001
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without the recombinase expression plasmid into CHO cells
containing the MI-HAC vector (platform
+/recombinase
2, n=3).
The second experiment involved co-transfection of the recombi-
nase expression and recombinant assay plasmids in CHO cells
containing the HAC vector without the multi-integrase platform
(platform
2/recombinase
+, n=3). In each transfection, cells were
seeded into ten 10-cm tissue culture dishes at 24 h post-
transfection and placed under selection with G418 at 48 h post-
transfection. Cells were selected for 12 days, then assessed for
colony numbers. Data were corrected for average colony numbers
in one of the ten dishes (Fig. 2B). There were approximately 10–
460-fold more colonies observed under the platform
+/recombi-
nase
+ conditions, compared with the control conditions (plat-
form
+/recombinase
2); and approximately 6–73-fold more colo-
nies observed under the platform
+/recombinase
+ conditions
compared with the platform
2/recombinase
+ transfection. These
results suggested that integrases and phage attP sites on the MI-
HAC vector were functional in CHO cells, and that these
integrases yielded higher total colony numbers compared with
FLPe.
To determine the frequency of the site-specific recombination
event at the recombination sites on the MI-HAC vector, we
employed genomic PCR analysis. Using the appropriate primers
(PGK5/G418 3AS), the expected amplicon was detected in 30 of
31 (96.8%) colonies for WC31 integrase (Fig. 2C). In other
recombinases, R4, TP901-1, Bxb1 integrases and FLPe showed
average recombination frequencies of approximately 82.4, 39.3,
94.1 and 17.2%, respectively (Fig. 2C). A recombination event in
the absence of the respective recombinases was not observed.
FISH analyses were performed on cells to examine if each
recombinant assay plasmid was inserted into the MI-HAC vector.
In the pool of cells obtained from each recombinase, the FITC
signal (green) indicating the recombinant assay plasmid localized
at the MI-HAC vector (red; Fig. 2D). These results showed that
the site-specific insertion of foreign DNA into the MI-HAC vector
was achieved by integrases and FLPe.
Generation of GFP-expressing cells with the MI-HAC
vector or via random integration
Based on the likely activity of phage integrases in mediating
recombination events in CHO cells, we tested whether the MI-
HAC vector with integrases was able to produce cells expressing
the gene of interest more efficiently than the conventional random
integration method. The transfection experiments were carried out
with pNeo-attB EGFP or pEGFP N1, which both contained the
strong CMV enhancer coupled to the enhanced green fluorescent
protein (EGFP) gene (Fig. 3A). Before transfection, the pEGFP N1
was linearized at the AseI site, upstream from the CMV promoter.
The host cells used in the transfection experiments were CHO
cells carrying the MI-HAC vector. Each transfection was subjected
to G418 selection, and colony numbers were assessed. In one such
experiment, approximately 5–17-fold more colonies under G418
selective pressure for 12 days were observed when the linearized
pEGFP N1 was transfected into CHO cells (random integration
method), compared with pNeo-attB EGFP with the correct
integrase expression plasmid (MI-HAC method). Following
transfection after 12 days in G418 selection medium, the
transfected cells were analyzed by flow cytometry to examine
the proportion of GFP expression CHO colonies. As a result, the
GFP-positive cells obtained by the MI-HAC method with WC31
integrase comprised 89.9% of the total cell population (Fig. 3B,
Table 1). The negative control employed was CHO cells without a
GFP expression cassette. Similar experiments using R4, TP901-1
and Bxb1 integrases demonstrated the proportion of GFP-positive
cells to be 71.4, 75.7 and 75.0%, respectively (Fig. 3B, Table 1).
Although GFP-positive cells obtained by the random integration
method comprised 59.6%, there was not a great difference in the
proportion of GFP-positive cells by the MI-HAC vector or the
random integration methods (Table 1). However, we observed a
wide distribution of GFP expression in the pool of cells obtained
following application of the random integration method (Fig. 3B).
In addition, we observed the expression of GFP using fluorescence
microscopy in CHO colonies. As a result, in colonies obtained by
the MI-HAC method, we observed homogenous GFP expression
(nearly every cell expressed GFP in the clonal population) in many
colonies (Fig. 3C, Table 1). In contrast, we observed only 10.0% of
colonies with homogenous GFP expression after the random
integration method (Table 1). Nearly 90.0% of colonies consisted
of heterogenous GFP-expressing cells (a mixture of very little or no
GFP-expressing cells in the clonal population) following random
integration (Fig. 3C).
Transfer of the MI-HAC vector to mammalian cell
An important application of the MI-HAC vector is its potential
use as a vector for generation of transgenic cells. At present, the
most commonly used method to introduce HACs into recipient
target cells is microcell-mediated chromosome transfer (MMCT).
As assessed by FISH using the human-specific COT1 probe, CHO
cells possessed an independently segregating mini-chromosome
corresponding to the MI-HAC vector (Fig. 4B). The MI-HAC
vector was introduced into mouse A9 cells by MMCT. After
selection with hygromycin B, eight clones were obtained. We
confirmed that these drug-resistant A9 clones contained the MI-
HAC vector by genomic PCR, with FISH analysis revealing that
the MI-HAC vector was segregated independently, with neither
host genome insertion nor translocation in all eight clones (Fig. 4C).
Next, we examined whether an integrase was functional in another
mammalian cell line, mouse A9. Similar experiments in CHO cells
using WC31 integrase and the GFP expression plasmid were
carried out in the A9 cells. After 12 days in G418 selection
medium, flow cytometry analysis of these cell populations was
conducted. Consequently, the GFP-positive cells acquired by the
MI-HAC method with the WC31 integrase comprised 93.4% of
the total cell population (Fig. 4D). The negative control employed
was A9 cells without a GFP expression cassette. Similar to the
CHO cells, we observed homogenous GFP expression in most A9
colonies (Fig. 4E).
Discussion
In this study, we constructed a HAC vector with multi-integrase
recombination sites. We also demonstrate that phage integrases,
WC31, R4, TP901-1 and Bxb1, mediated recombination efficient-
ly between att sites; and that de novo integrases combined with the
HAC vector to produce transgenic cells more efficiently than
conventional methods in mammalian cells. It was also shown that
the MI-HAC vector was transferable to cultured cell lines by
MMCT.
The recombination activity for WC31, R4, TP901-1 and Bxb1
integrases was assessed in CHO cells carrying the MI-HAC vector.
The results of these recombination assays indicated that these
integrases conferred higher recombination activity (39.3–96.8%) in
mammalian cells compared with FLPe (17.2%). However, whether
codon optimization of integrases gave high recombination activity
was not tested. These integrases may be better suited for cassette
exchange reactions as compared with Cre or FLP [18]. The
proportion of plasmid insertion into the phage attP sites on the MI-
Multi-Integrase System on a HAC Vector
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higher compared with insertion into the 59 HPRT-loxP site of the
21HAC1 by HPRT reconstitution (33.3%) or into the 39 neo-loxP
site of the 21DqHAC/21DpqHAC by neomycin gene reconstitu-
tion (37.5%) [38,39,46].
To increase the speed and efficiency of generating transgenic
cells, the MI-HAC system combined with integrases was applied.
This MI-HAC system consists of four main components: the MI-
HAC vector, the MI-HAC cell line, the gene insertion plasmid and
the integrase expression plasmid. We revealed that the MI-HAC
method combined with integrases allows us to obtain transgenic
cells more efficiently than the random integration method. Based
on these favorable results from the MI-HAC system, in particular
with WC31 integrase, it was proposed that the cell selection process
could be omitted altogether. The phenomenon of heterocellular
transgene expression in a clonal subpopulation of cells occurred
rarely via the MI-HAC method as compared with the random
integration method. As reported previously, the HAC vector
enables stable expression of the inserted gene, and is not affected
by position in the genome [38,39,47]. Our data suggested a
genomic targeting system using the MI-HAC vector with
integrases enabled transgenes to be targeted to a pre-determined
locus, thereby limiting the effects of position and allowing
transgenic cells to be generated more efficiently and robustly than
the random integration method. These results are specific for the
MI-HAC vector, the likelihood of these results carrying over to
normal mammalian chromosomes was not tested.
Generation of cell lines often requires the use of cell clones
containing stably integrated transgenes. Conventional methods such
as random integration can lead to a broad variation in expression
profiles between cells due to the differences in variable position effects
on the function of a specific transgene. Another approach is
generation of site-specific targeting cell lines using WC31 and R4
integrases [48]. However, this approach requires confirmation that
the R4 plasmid inserted locus is not subject to genomic positional
effects. Recent studies have found that aberrant events, including
chromosomal rearrangements in the target cell genome, were
induced by the WC31 and R4 integrases [49,50,51,52]. In contrast,
due to the transfer ability of the MI-HAC vector, effects such as
chromosomal rearrangement do not occur with the phage integrases.
We demonstrated the transfer of the MI-HAC vector from CHO
cells to mouse A9 cells by MMCT. We previously demonstrated that
the HAC vector can be transferred into various cell types, such as
mouse embryonic stem cells, human primary fibroblasts, as well as
hematopoietic and mesenchymal stem cells [41,47]. We confirmed
thatWC31integrase was functional in mouse A9 cells, and the MI-
HAC vector with WC31integrase can be applied as an efficient gene
expression system in various cell environments.
In addition to chromosomal integration events, there are certain
instances where chromosomal deletion or excision is desired, such
as in the generation of knockout or conditional knockout
transgenic animals. One of the techniques to accomplish deletion
or excision of a sequence of interest is through the use of site-
specific recombinases [53]. Recent studies have reported that
phage integrases, such as WC31, R4 and TP901-1, were functional
in the mammalian embryonic environment and had the potential
for creation of transgenic animals and modification of the
mammalian genome in vivo [26,54,55].
In this study, we combined phage integrase-mediated recombina-
tion technology with the HAC vector. The MI-HAC system is able to
efficiently and precisely carry out recombination in mammalian cells,
thereby making it a valuable unique genetic tool for investigating
gene function, gene therapy and animal transgenesis.
Materials and Methods
Construction of the multi-integrase platform plasmid
The multi-integrase platform plasmid was constructed using the
Multisite Gateway
TM kit (Invitrogen, Carlsbad, CA, USA) as
previously described [44,45]. The PCR fragments for FRT-PGK-
WC31 attP, PGK-R4 attP, PGK-TP901-1 attP and PGK-Bxb1
attP (Table S1) flanked by the appropriate gateway attB sites were
created in two steps. First, PGK-hyg (Clontech, Palo Alto, CA,
USA) was used as a template for PCR amplification with primer
pair F1 and R1 (Table S2). These products then served as
templates for the second PCR amplification step with the primer
pair F1 and R2 (F2 and R2 for FRT-PGK-WC31 attP; Table S2).
The gateway attB-flanked PCR product was recombined with a
donor vector containing the corresponding gateway attP signals in a
BP reaction to generate an entry clone. Approximately 150 ng of
Table 1. GFP expression profiles of the transfected CHO cells.
Integrase Proportion GFP-positive cells (%)
a Homogenous GFP expression colonies (%)
b
WC31 89.9 87.5
R4 71.4 85.0
TP901-1 75.7 86.4
Bxb1 75.0 77.3
Random integration 59.6 10.0
aAnalysis via flow cytometry.
bAnalysis via fluorescence microscopy.
CHO cells obtained by the multi-integrase HAC or the random integration method were cultured in the presence of G418 and GFP expression was analyzed by flow
cytometry. Additionally, the ratio of homogenous GFP-expressing colonies was evaluated by fluorescence microscopy.
doi:10.1371/journal.pone.0017267.t001
Figure 3. Comparison of the efficiency in generating transgenic cells. (A) Schematic diagram of the insertion of the plasmid containing the
CMV promoter and the EGFP gene in the multi-integrase HAC vector or host chromosome. Under both conditions, cells were incubated with the
reagent/DNA mixture for 24 h and selected with G418 until drug-resistant cell pools were obtained. (B) Flow cytometry analysis of the fluorescent
profile of transfected CHO cells on day 12 following selection by G418 after transfection. The bars indicate the GFP-expressing cell population. (C)
Expression of the inserted EGFP gene was tracked in cells by fluorescence microscopy. Typical images (bright field, upper panels; fluorescence, lower
panels) of cells obtained by the multi-integrase HAC vector with integrases and random integration are shown. Scale bar, 100 mm.
doi:10.1371/journal.pone.0017267.g003
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221 P5-P4, pDONR 221 P4r-P3r, pDONR 221 P3-P2) were mixed
with 2 ml of BP clonase
TM II enzyme mix, and adjusted to 10 ml
with TE buffer. The mixture was then incubated at 25uC for 1 h to
create four entry clones (pENTR L1-FRT-PGK-WC31-R5,
pENTR L5-PGK-R4-L4, pENTR R4-PGK-TP901-1-R3, pENTR
L3-PGK-Bxb1-L2). After the BP reaction, the enzymes were
inactivated by treatment with Proteinase K for 10 min at 37uC.
CompetentMach1
TMT1
RE. coli (Invitrogen)was used accordingto
the supplier’s instruction. After transformation, the cell solution was
diluted with SOC medium and incubated at 37uC for 1 h. The
transformation reactions were then spread onto LB agar plates
containing 50 mg/ml kanamycin (Km) and incubated for 14 h at
37uC. The sequence of the four pENTRs was confirmed by DNA
sequencing. The destination vector (pDEST) contained the R1-
ccdB-Cm
R-R2 cassette (Invitrogen), a single PGK promoter and
loxP-39 HPRT cassette. The backbone vector was isolated by blunt
PCR from the plasmid V901-39HPRT-loxP [39] using the primers
PGK2362 and loxP4548. The R1-ccdB-Cm
R-R2 cassette was
ligated into the blunt V901-39HPRT-loxP plasmid. To construct
the destination vector containing a toxic ccdB gene, ccdB survival
TM
competent cells (Invitrogen) were used for propagation according to
the supplier’s instruction. After transformation, the cell solution was
diluted with SOC medium and incubated at 37uC for 1 h. The
transformation reactions were then spread onto LB agar plates
containing 20 mg/ml chloramphenicol (Cm) and incubated for 18 h
at 37uC. Sequence and orientation of pDEST and the R1-ccdB-
Cm
R-R2 cassette was confirmed by DNA sequencing. The four
entry clones were recombined with a destination vector to generate
the multi-integrase platform plasmid. Before this reaction, the
pDEST was linearized at the BglII site, between a ccdB gene and a
Cm
R gene. Around 20 ng of each entry clone and 80 ng of
destination vector were mixed with 2 ml of LR clonase II Plus
enzyme mix, and made up to 10 ml with TE buffer. The mixture
wasthen incubatedat25uC for16 h.Afterthis reaction, the enzyme
was inactivated by treatment with Proteinase K for 10 min at 37uC.
Competent Mach1 T1
R E. coli were used for transformation.
Following transformation, the cell solution was diluted with SOC
medium and incubated at 37uC for 1 h. The transformation
reactions were then spread onto LB agar plates containing 100 mg/
ml ampicillin (Amp) and incubated for 14 h at 37uC. The multi-
integrase plasmid carried the non-functional loxP-39 HPRT for
targeting the HAC vector. Cre recombinase-catalyzed integration
required a functional HPRT gene.
DNA constructs
The mammalian codon-optimized integrase expression plas-
mids, pCMV-WC31, pCMV-R4, pCMV-TP901-1 and pCMV-
Figure 4. The multi-integrase HAC vector is transferable to other cell lines. (A) Microcell-mediated chromosome transfer (MMCT) of the
multi-integrase HAC vector into mouse A9 cells and subsequent introduction of gene expression cassettes. (B) Typical FISH image of CHO cells
carrying the multi-integrase HAC vector. The arrowhead indicates the multi-integrase HAC vector. (C) Shown is a representative metaphase spread
hybridized to the human COT-1 probe (red) in A9 hybrids. (D) By flow cytometry analysis, the proportion of GFP-positive transfected A9 cells was
determined. The gray curve indicates cells without a GFP expression cassette, the green curve indicates cells obtained by the multi-integrase HAC
vector with WC31 integrase. The bar indicates the GFP-expressing cell population. (E) GFP expression was detected in the G418-resistant A9 cells by
fluorescence microscopy. Representative images (bright field, upper panels; fluorescence, lower panels) of cells obtained with the multi-integrase
HAC vector with WC31 integrase are shown. Scale bar, 100 mm.
doi:10.1371/journal.pone.0017267.g004
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and Bxb1 integrase were synthesized de novo (WC31: Codon device,
Cambridge, MA, USA; others, Invitrogen) based on the published
WC31, R4, TP901-1 and Bxb1 integrase coding sequences
(GenBank accession numbers: WC31, CAA07153; R4,
BAA07372; TP901-1, CAA59475; Bxb1, AAG59740). The native
amino acid sequence but with mammalian codon usage of de novo
synthesized integrases are shown in Figures S1, S2, S3 and S4.
The WC31, R4, TP901-1 and Bxb1 coding sequences were cloned
into mammalian expression vectors pVAX1 (Invitrogen) driven by
the high expressing CMV promoter. The synthesized sequence of
WC31 integrase was digested with KpnI and XbaI and cloned into
the KpnI and XbaI sites of pVAX1. The R4, TP901-1 and Bxb1
integrases were digested with NheI and XhoI and cloned into the
equivalent sites of pVAX1. The FLPe expression vector pOG44
(Invitrogen) was used as the backbone for pCMV-FLPe.
Recombinant assay plasmids were used for integrase- or FLPe-
mediated recombination assays in CHO cells. This plasmid
carried the WC31, R4, TP901-1, Bxb1 attB or FRT sites (Table
S1) positioned at the 59 end of a neomycin-resistance gene (pNeo-
WC31 attB, pNeo-R4 attB, pNeo-TP901-1 attB, pNeo-Bxb1 attB
or pNeo-FRT). The neomycin-resistance gene was isolated by
blunt PCR from pIRES Neo2 (Clontech, Mountain View, CA,
USA) using the primers Neo F and Neo R. This PCR product was
blunt cloned into the EcoRV/SmaI-digested pSLR-test (Toyobo,
Osaka, Japan), replacing the SLR gene and creating the plasmid
pNeo. Sequence and orientation of a neomycin-resistance gene
was confirmed by DNA sequencing. The WC31 attB, Bxb1 attB
and FRT site was synthesized by Integrated DNA technologies
Inc. (Coralville, IA, USA). The R4 attB and TP901-1 attB sites
were synthesized by Invitrogen. The WC31 attB and R4 attB sites
were digested with SalI and cloned into the SalI site of pNeo. The
TP901 attB and FRT site was digested using ClaI and cloned into
the equivalent site of pNeo. The Bxb1 attB site was digested with
NheI and cloned into the NheI-digested pNeo. Orientation of each
of the attB and FRT sites was confirmed by DNA sequencing.
The plasmid pNeo-attB EGFP was used for GFP expression cell
assays in mammalian cells. The CMV promoter and EGFP gene
were amplified by PCR from the pEGFP N1 (Clontech) lacking
the BamHI recognition sequence in the multi-cloning site using the
primers CMV-GFP F and CMV-GFP R. The PCR product was
digested with BamHI and cloned into the equivalent site of pNeo-
attB, creating pNeo-WC31 attB EGFP, pNeo-R4 attB EGFP,
pNeo-TP901-1 attB EGFP and pNeo-Bxb1 attB EGFP. Sequence
and orientation of the CMV promoter and EGFP gene were
confirmed by DNA sequencing.
Cell culture and DNA transfection
CHO cells carrying the HAC vector were maintained at 37uC
in Ham’s F-12 nutrient mixture (Invitrogen) supplemented with
10% fetal bovine serum (FBS; JRH Biosciences, Lenexa, KS,
USA). The HAC vector used in this study was 21HAC1 [39].
Mouse A9 cells used as a fusion recipient for chromosome transfer
were maintained at 37uC in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma, St Louis, MO, USA) plus 10% FBS. A9 hybrids
carrying the MI-HAC vector were selected in a growth medium
containing 800 mg/ml hygromycin B (Wako, Osaka, Japan).
For DNA transfection to construct the MI-HAC vector, 1610
6
HPRT-deficient CHO cells containing the HAC vector were
seeded in wells of 6-well tissue culture plates 24 h before
transfection. Approximately 3 mg multi-integrase platform plasmid
carrying loxP and 39HPRT were co-transfected with 1 mg Cre-
expression plasmid pBS185 (Invitrogen) using Lipofectamine2000
(Invitrogen). CHO clones containing the HAC vector in which
site-specific insertion of the multi-integrase plasmid had occurred
were selected using HAT (Sigma) over a period of 12 days.
Genomic PCR analyses
Genomic DNA from cell lines was extracted using a genomic
extraction kit (Sigma). PCR analyses were carried out using
standard techniques. The primer pairs used for confirmation of the
multi-integrase platform were WC31 F1 and Bxb1 R3. The primer
pairs used for detection of HPRT gene reconstitution were Trans
L1 and Trans R1, along with loxP4548 and hyg696. The primer
pairs utilized for detection of neomycin gene reconstitution were
PGK5 and G418 3AS.
Fluorescence in situ hybridization (FISH)
FISH analysis of CHO and A9 cells was performed with either
fixed metaphase or interphase nuclei using digoxigenin-labeled
(Roche, Basel, Switzerland) human COT1 DNA (Invitrogen) and
biotin-labeled DNA (pNeo-WC31 attB, pNeo-R4 attB, pNeo-
TP901-1 attB, pNeo-Bxb1 attB or pNeo-FRT) as described
previously [56]. Chromosomal DNA was counterstained with
DAPI (Sigma). The images were captured using the Argus system
(Hamamatsu Photonics, Hamamatsu, Japan) or NIS elements
(Nikon, Tokyo, Japan).
Assay for integrase-mediated recombination on the MI-
HAC vector
For DNA transfection, 1610
6 CHO cells containing the MI-
HAC vector were seeded into wells of 6-well tissue culture plates
24 h before transfection. CHO cells carrying the MI-HAC vector
were co-transfected with 3 mg recombinant assay plasmid and 1 mg
the corresponding recombinase expression plasmid (platform
+/
recombinase
+) using Lipofectamine2000 (Invitrogen). As a nega-
tive control for integration into the MI-HAC vector, parallel
transfections were carried out with a recombinant assay plasmid
lacking a recombinase expression plasmid (platform
+/recombi-
nase
2). CHO cells containing the HAC vector without the multi-
integrase platform were co-transfected with a recombinant assay
plasmid and a recombinase expression plasmid (platform
2/
recombinase
+). The cells were seeded into ten 10-cm dishes at
24 h post-transfection and placed under selection with 600 mg/ml
G418 (Invitrogen) at 48 h post-transfection. Cells were selected for
12 days, then assessed for colony numbers through the use of
crystal violet dye. Solutions containing 1% crystal violet (Merck
KGaA, Darmstadt, Germany) with 70% ethanol (Wako, Osaka,
Japan) were used to simultaneously fix and stain surviving cells to
make them easily visible.
For the GFP expression assay, CHO or A9 cells containing the
MI-HAC vector were co-transfected using pNeo-attB-EGFP with
the corresponding integrase expression plasmid. At 24 h post-
transfection, the cells were seeded into three 10-cm dishes, and at
48 h post-transfection the medium was replaced with F12
containing 600 mg/ml G418 or DMEM supplemented with
800 mg/ml G418. Selective pressure was maintained for 12 days,
after which the G418-resistant colonies were analyzed by flow
cytometry and observed using fluorescence microscopy. To
compare with the MI-HAC method, parallel transfections were
done with the linearized pEGFP N1. Before transfection, the
pEGFP N1 was linearized at the AseI site upstream of the CMV
promoter.
Flow cytometry
The ratio of cells expressing GFP was determined, and
transfected cells under selective pressure were analyzed with a
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cells in our experiments, all samples were stained with propidium
iodide (PI). Between 23,000–26,000 events were acquired for each
sample. The GFP and PI were excited with a 488 nm argon laser,
and were detected with band-pass filters of 530/40 nm and 613/
20 nm, respectively. To set the parameters for flow cytometry
analysis, non-transfected cells were used as negative controls. Flow
cytometry data analysis and figure generation was performed using
FlowJo software (Tree Star Inc, Ashland, OR, USA).
Microcell-mediated chromosome transfer (MMCT)
MMCT was performed according to standard protocols
[56,57]. The MI-HAC vector was transferred from CHO cells
into A9 cells using MMCT. Briefly, microcells were prepared by
centrifuging the CHO cells and fusing 5610
6 A9 cells with 47%
polyethylene glycol 1000 (Wako). The A9 hybrids were selected
with 800 mg/ml hygromycin B (Wako) and picked for expansion.
Supporting Information
Figure S1 Nucleotide sequence of mammalian codon-
optimized WC31 integrase. The nucleotide sequence of WC31
integrase used in this study. A mammalian codon-optimized WC31
integrase gene was synthesized de novo according to the native
WC31 integrase amino acid sequence.
(DOC)
Figure S2 Nucleotide sequence of the mammalian
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